• Coherus Oncology held its annual shareholder meeting on May 27, 2026, with voting on one item completed on May 29, 2026.
• Shareholders backed a reduction in the exercise price of certain outstanding stock options; the vote authorized the change but did not confirm it was implemented.
• Shareholders also ratified Ernst & Young as independent auditor for the fiscal year ending Dec. 31, 2026.
• Investors approved an increase in shares reserved for issuance under the Amended and Restated 2014 Equity Incentive Award Plan.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Coherus Oncology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-068615), on June 01, 2026, and is solely responsible for the information contained therein.